 |
|
Sentinel Lymph Node Biopsy for Cutaneous Melanoma
The Stanford Experience, 1997-2004
David R. Berk, MD;
Denise L. Johnson, MD;
Alison Uzieblo, MD;
Michaela Kiernan, PhD;
Susan M. Swetter, MD
Arch Dermatol. 2005;141:1016-1022.
Objective To review sentinel lymph node (SLN) data from Stanford University Medical Center from January 1, 1997, to January 1, 2004, including rates of SLN positivity according to 2002 American Joint Committee on Cancer (AJCC) tumor classification, relation to other clinical and pathologic prognostic factors, and rates and sites of melanoma recurrence.
Design Retrospective case series.
Setting Stanford University Medical Center and Stanford melanoma clinics.
Patients A total of 274 consecutive patients with primary melanoma who underwent SLN biopsy (SLNB) between January 1, 1997, and January 1, 2004, or who were referred to the Stanford melanoma clinics after SLNB and were followed up through March 2005.
Interventions All patients underwent standard wide local excision of their primary tumors and SLNB with intradermal injection of isosulfan blue dye and/or technetium sulfur colloid.
Main Outcome Measure Rates of SLN positivity per 2002 AJCC tumor classification, relation to other clinical and pathologic prognostic factors, and rates and sites of melanoma recurrence in node-negative and node-positive patients.
Results Positive SLNs were detected in 39 (15%) of 260 cases, including 0 (0%) of 45 for cutaneous melanomas 1.0 mm thick or less (T1), 21 (18%) of 115 for melanomas 1.01 to 2.0 mm thick (T2), 12 (19%) of 64 for melanomas 2.01 to 4.0 mm thick (T3), and 5 (16%) of 32 for melanomas thicker than 4.0 mm (T4). Median Breslow depths were 1.89 mm for SLN-positive biopsy specimens and 1.50 mm for SLN-negative biopsy specimens (P = .07). The recurrence rate was 46% among SLN-positive patients, with a median time to recurrence of 8 months. Bivariate analysis revealed SLN positivity to be associated with AJCC tumor classification (P = .02), location on the trunk (P = .03), and presence of ulceration (P = .03). By multivariate logistic regression, ulceration (P = .01) was predictive of SLN positivity, whereas SLN status (P< .001), ulceration (P = .02), and location (P = .03) were predictive of recurrent disease.
Conclusion Data from the past 8 years confirm the accuracy and prognostic value of SLNB in cutaneous melanoma and the low rate of regional nodal recurrence for SLN-negative patients.
Author Affiliations: Departments of Dermatology (Drs Berk and Swetter), Surgery (Drs Berk and Johnson), and Pathology (Dr Uzieblo), and Stanford Prevention Research Center (Dr Kiernan), Stanford University Medical Center, Stanford, Calif; and the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif (Dr Swetter). Dr Uzieblo is now with William Beaumont Hospital, Royal Oak, Mich.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma
Taylor et al.
JCO 2007;25:869-875.
ABSTRACT
| FULL TEXT
Natural Killer Receptors on CD8 T Cells and Natural Killer Cells from Different HLA-C Phenotypes in Melanoma Patients.
Campillo et al.
Clin. Cancer Res. 2006;12:4822-4831.
ABSTRACT
| FULL TEXT
Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant Melanoma
Lewis et al.
JCO 2006;24:3157-3163.
ABSTRACT
| FULL TEXT
Chemokines, chemokine receptors, and cancer metastasis
Kakinuma and Hwang
J. Leukoc. Biol. 2006;79:639-651.
ABSTRACT
| FULL TEXT
Cutaneous Malignant Melanoma
Cummins et al.
Mayo Clin Proc. 2006;81:500-507.
ABSTRACT
| FULL TEXT
|
